BEAM
NASDAQBeam Therapeutics Inc.
Price$29.51+1.14 (+4.00%)
01:30 PM07:45 PM
News · 26 weeks59-17%
2025-12-072026-05-31
Mix2690d
- Insider11(42%)
- Other8(31%)
- SEC Filings6(23%)
- Earnings1(4%)
Latest news
25 items- PRAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumUSA News Group News CommentaryIssued on behalf of Avaí Bio, Inc.As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α-Klotho anti-aging program.NEW YORK, May 28, 2026 /CNW/ -- Cell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer non-CF franchises CASGEVY and JOURNAVX contributing more than 25% of year-over-year growth. Alnylam Pharmaceuticals delivered its first-ever $1 billion product revenue quarter. Beam Therapeutics presented updated
- PRBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International ConferenceCAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla. "At Beam, we are committed to leading innovation in the AATD community, with a goal of transforming dise
- PRBeam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 13, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Beam Therapeutics as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.
- PRBeam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare ConferenceCAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic
- PRBeam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Risto-cel is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of SCD. "The comprehensive analyses being presented at EHA2026 further underscore the potential of risto-cel to c
- SECSEC Form 10-Q filed by Beam Therapeutics Inc.10-Q - Beam Therapeutics Inc. (0001745999) (Filer)
- SECBeam Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Beam Therapeutics Inc. (0001745999) (Filer)
- PRBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesRecent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runwa
- SECSEC Form DEFA14A filed by Beam Therapeutics Inc.DEFA14A - Beam Therapeutics Inc. (0001745999) (Filer)
- SECSEC Form DEF 14A filed by Beam Therapeutics Inc.DEF 14A - Beam Therapeutics Inc. (0001745999) (Filer)
- SECSEC Form 144 filed by Beam Therapeutics Inc.144 - Beam Therapeutics Inc. (0001745999) (Subject)
- INSIDERSEC Form 4 filed by Evans John M.4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Simon Amy4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Bellon Christine4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Cavanagh Bethany J4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Ciaramella Giuseppe4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Bellon Christine4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Cavanagh Bethany J4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Simon Amy4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Emany Sravan Kumar4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Ciaramella Giuseppe4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- INSIDERSEC Form 4 filed by Evans John M.4 - Beam Therapeutics Inc. (0001745999) (Issuer)
- PRBeam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of MedicinePrestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution of Red Blood Cell Dysfunction and Reduced Time in Hospital Driven by a Median of One Cell Collection Cycle and Rapid Engraftment U.S. Biologics License Application (BLA) Submission for risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the publication of data from
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
- PRBeam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentTreatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and E
BEAM FAQ
7 questionsWhat does Beam Therapeutics Inc. do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders...Where does BEAM stock trade?
Beam Therapeutics Inc. (BEAM) is listed on NASDAQ.What sector and industry is BEAM in?
Beam Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Beam Therapeutics Inc. go public?
Beam Therapeutics Inc. (BEAM) completed its IPO in 2020.What are analysts saying about BEAM?
Beam Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-02-20. Recent price targets range from $3900.00 to $4200.00.What companies are similar to BEAM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BEAM side-by-side with any of them on Quantisnow.How can I track BEAM on Quantisnow?
Quantisnow aggregates Beam Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BEAM to receive live email and push alerts on every new disclosure.